Phaseline

Companies › EnnovaBio

EnnovaBio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ENN0403–Phase 2Diabetic Macular Edema (DME)–
ENC0653–Phase 1HealthyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06708260ENN0403Phase 2Diabetic Macular Edema (DME)OphthalmologyAug 2026
NCT07684196ENC0653Phase 1HealthyOtherDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Atsena Therapeutics PolyActiva Tortugas Neuroscience Ashvattha Therapeutics Vantage Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.